Methamphetamine Use Disorder

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Methamphetamine Use Disorder is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

10/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Recruiting5 · 50%

Completed2 · 20%

Active, not recruiting1 · 10%

Terminated1 · 10%

Not yet recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder

Recruiting·—·Phase 2·NCT06788587·80 enrolled

Ketamine for Methamphetamine Use Disorder

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06496750·120 enrolled

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

Recruiting·—·Phase 2·NCT06538285·12 enrolled

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

Recruiting·PPortland VA Research Foundation, Inc·Phase 1/2·NCT04982796·30 enrolled

Exploring the Mechanisms and Efficacy of Cerebellum-Medial Prefrontal Cortex-Based Paired-Pulse Repetitive Transcranial Magnetic Stimulation for Methamphetamine Use Disorder

Recruiting·SShanghai Mental Health Center·Preclinical·NCT06457230·90 enrolled

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT05322954·12 enrolled

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Not yet recruiting·KKirby Institute·Phase 2·NCT07509112·40 enrolled

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Completed·UUniversity of Texas Southwestern Medical Center·Phase 3·NCT03078075·403 enrolled

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

Completed·—·Phase 1/2·NCT01982643·49 enrolled

The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT05711862·7 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)